Response to [Comment on is clozapine use a risk of hematological malignancies? Insights from a meta‐analysis “Clozapine and Malignancy Risk”]

Omar Kassar; Omar Shaheen; Moaz Elsayed Abouelmagd; Muataz Kashbour

doi:10.1111/pcn.13856

August 1, 2025Psychiatry and Clinical Neurosciences

Response to [Comment on is clozapine use a risk of hematological malignancies? Insights from a meta‐analysis “Clozapine and Malignancy Risk”]

View Full Paper

Ask AI

Bookmark

Share

Key Points

Clozapine use may involve risks related to hematological malignancies, raising important clinical considerations.
Meta-analysis findings suggest a significant association between clozapine and hematological malignancies, warranting caution.
This commentary reflects on existing evidence about clozapine's malignancy risk, leading to continued debate in psychiatric practice.
The implications of clozapine safety in hematological contexts call for further comprehensive studies.

Implication

Comment discusses the potential link between clozapine use and hematological malignancies, implying ongoing concerns.

Abstract

This article relates to Comment on: is clozapine use a risk of hematological malignancies? Insights from a meta‐analysis “Clozapine and Malignancy Risk”.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kassar et al. (2025) studied this question.

synapsesocial.com/papers/68af56f4ad7bf08b1eadce2f https://doi.org/10.1111/pcn.13856

View Full Paper

Ask AI

Bookmark

Share

Response to [Comment on is clozapine use a risk of hematological malignancies? Insights from a meta‐analysis “Clozapine and Malignancy Risk”]

Key Points

Implication

Abstract

Discussion

Cite This Study

Response to [Comment on is clozapine use a risk of hematological malignancies? Insights from a meta‐analysis “Clozapine and Malignancy Risk”]

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading